Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study

References 41

1. 1.

   Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carillo MC, Thies W, Morrison-Bogorad M, Wagster MV, Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Assocation workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-92.

   Not in our library10.1016/j.jalz.2011.03.003

2. 2.

   McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morric JC, Rosser MN, Scheltens P, Thies W, Weintraub S, Phelps CH. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Assocation Workgrou. Alzheimers Dement. 2011;7(3):263-9.

   Not in our library10.1016/j.jalz.2011.03.005

3. 3.

   Albert MS, De Kosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement. 2011;7(3):270-9.

   Not in our library10.1016/j.jalz.2011.03.008

4. 4.

   Jack CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carillo M, Thies W, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):257-62.

   Not in our library10.1016/j.jalz.2011.03.004

5. 5.

   Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet neurology. 2014;13(6):614-629.

   Not in our library10.1016/s1474-4422(14)70090-0

6. 6.

   Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Crutch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genthon R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O'Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's & dementia the journal of the Alzheimer's Association. 2016;12(3):292-323.

   Not in our library10.1016/j.jalz.2016.02.002

7. 7.

   Jack CR, Knopman DS, Weigand SD, Wiste HJ, Vemuri P, Lowe V, Kantarci K, Gunter JL, Senjem ML, Ivnik RJ, Roberts RO, Rocca WA, Boeve BF, Petersen RC. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol. 2012;71(6):765-75.

   Not in our library10.1002/ana.22628

8. 8.

   Knopman DS, Jack CR, Wiste HJ, Weigand SD, Vemuri P, Lowe VJ, Kantarci K, Gunter JL, Senjem ML, Mielke MM, Roberts RO, Boeve BF, Petersen RC. Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann Neurol. 2013;73(4):472-480.

   Not in our library10.1002/ana.23816

9. 9.

   Mormino EC, Betensky RA, Hedden T, Schultz AP, Amariglio RE, Rentz DM, Johnson KA, Sperling RA. Synergistic Effect of beta-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals. JAMA neurology. 2014;71(11):1379-85.

   Not in our library10.1001/jamaneurol.2014.2031

10. 10.

    Vos SJ, Xiong C, Visser PJ, Jasielec MS, Hassenstab J, Grant EA, Cairns NJ, Morris JC, Holtzman DM, Fagan AM. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet neurology. 2013;12(10):957-65.

    Not in our library10.1016/s1474-4422(13)70194-7

11. 11.

    van Harten AC, Smits LL, Teunissen CE, Visser PJ, Koene T, Blankenstein MA, Scheltens P, van der Flier WM. Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. 2013;81(16):1409-16.

    Not in our library10.1212/wnl.0b013e3182a8418b

12. 12.

    Caroli A, Prestia A, Galluzzi S, Ferrari C, van der Flier WM, Ossenkoppele R, Van Berckel B, Barkhof F, Teunissen C, Wall AE, Carter SF, Scholl M, Choo IH, Grimmer T, Redolfi A, Nordberg A, Scheltens P, Drzezga A, Frisoni GB. Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. Neurology. 2015;84(5):508-15.

    Not in our library10.1212/wnl.0000000000001209

13. 13.

    Burnham SC, Bourgeat P, Dore V, Savage G, Brown B, Laws S, Maruff P, Salvado O, Ames D, Martins RN, Masters CL, Rowe CC, Villemagne VL. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. The Lancet Neurology. 2016;15(10):1044-53.

    Not in our library10.1016/s1474-4422(16)30125-9

14. 14.

    Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. The Lancet Neurology. 2015;14(1):114-124.

    Not in our library10.1016/s1474-4422(14)70252-2

15. 15.

    Johnson KA, Shultz A, Betensky RA, Becker JA, Sepulcre J, Rentz DM, Mormino EC, Chhatwal J, Amariglio RE, Papp K, Marshall GA, Albers M, Mauro S, Pepin LC, Alverio J, Judge K, Philiossaint M, Shoup T, Yokell D, Dickerson BC, Gomez-Isla T, Hyman BT, Vasdev N, Sperling R. Tau positron emission tomographic imaging in aging and early Alzheimer's disease. Annals of neurology. 2016;79(1):110-9.

    Not in our library10.1002/ana.24546

16. 16.

    Scholl M, Lockhart SN, Schonhaut DR, O'Neil JP, Janabi M, Ossenkoppele R, Baker SL, Vogel JW, Faria J, Schwimmer HD, Rabionovici GD, Jagust WJ. PET Imaging of tau deposition in the aging human brain. Neuron. 2016;89(5):971-982.

    Not in our library10.1016/j.neuron.2016.01.028

17. 17.

    Schwarz AJ, Yu P, Miller BB, Shcherbinin S, Dickson J, Navitsky M, Joshi AD, Devous MD, Mintun MS. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathologicalstages. Brain: a journal of neurology. 2016;139(Pt 5):1539-50.

    Not in our library10.1093/brain/aww023

18. 18.
    Tau and Aβ imaging, CSF measures, and cognition in Alzheimer’s disease · 2016

    No notice
19. 19.

    Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. The Lancet Neurology. 2003;2(10):605-13.

    Not in our library10.1016/s1474-4422(03)00530-1

20. 20.

    Jack CR, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, Hampel H, Jagust WJ, Johnson KA, Knopman DS, Petersen RC, Scheltens P, Sperling RA, and Dubois B. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-47.

    Not in our library10.1212/wnl.0000000000002923

21. 21.

    Roberts RO, Geda YE, Knopman DS, Cha RH, Pankratz VS, Boeve BF, Ivnik RJ, Tangalos EG, Petersen RC, Rocca WA. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69.

    Not in our library10.1159/000115751

22. 22.

    St Sauver JL, Grossardt BR, Leibson CL, Yawn BP, Melton LJ, Rocca WA. Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project. Mayo Clinic Proceedings. 2012;87(2):151-160.

    Not in our library10.1016/j.mayocp.2011.11.009

23. 23.

    Jack CR, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, Gunter JL, Senjem ML, Jones DT, Kantarci K, Machulda MM, Mielke MM, Roberts RO, Vemuri P, Reyes D, Petersen RC. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2016.

    Not in our library10.1016/j.jalz.2016.08.005

24. 24.

    Klunk WE, Koeppe RA, Price JC, Benzinger T, Devous M, Jagust W, Johnson KA, Mathis CA, Minhas D, Pontecorvo M, Rowe C, Skovronsky D, Minturn M. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET. Alzheimer's & dementia. 2015;11(1):1-15.

    Not in our library10.1016/j.jalz.2014.07.003

25. 25.

    Whitwell JL, Tosakulwong N, Weigand SD, Senjem ML, Lowe VJ, Gunter JL, Boeve BF, Knopman DS, Dickerson BC, Petersen RC, Jack CR. Does amyloid deposition produce a specific atrophic signature in cognitively normal subjects? Neuroimage Clin. 2013;2:249-57.

    Not in our library10.1016/j.nicl.2013.01.006

26. 26.

    Schwarz CG, Gunter JL, Wiste HJ, Przybelski SA, Weigand SD, Ward CP, Senjem ML, Vemuri P, Murray ME, Dickson DW, Parisi JE, Kantarci K, Weiner MW, Petersen RC, Jack CR. A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity. Neuroimage: Clinical. 2016;11:802-12.

    Not in our library10.1016/j.nicl.2016.05.017

27. 27.

    Jack CR, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, Lowe V, Senjem ML, Gunter JL, Reyes D, Machulda MM, Roberts R, Petersen RC. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain: a journal of neurology. 2015;138(Pt 12):3747-59.

    Not in our library10.1093/brain/awv283

28. 28.

    Raz L, Jayachandran M, Tosakulwong N, Lesnick TG, Wille SM, Murphy MC, Senjem ML, Gunter JL, Vemuri P, Jack CR, Miller VM, Kantarci K. Thrombogenic microvesicles and white matter hyperintensities in postmenopausal women. Neurology. 2013;80(10):911-8.

    Not in our library10.1212/wnl.0b013e3182840c9f

29. 29.

    Gouw AA, Seewann A, Vrenken H, van der Flier WM, Rozemuller JM, Barkhof F, Scheltens P, Geurts JJ. Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. Brain: a journal of neurology. 2008;131(Pt 12):3286-98.

    Not in our library10.1093/brain/awn265

30. 30.

    Vos SJ, Gordon BA, Su Y, Visser PJ, Holtzman DM, Morris JC, Fagan AM, Benzinger TL. NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers. Neurobiol Aging. 2016;44:1-8.

    Not in our library10.1016/j.neurobiolaging.2016.03.025

31. 31.

    Gordon BA, Blazey T, Su Y, Fagan AM, Holtzman DM, Morris JC, Benzinger TL. Longitudinal beta-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. JAMA neurology. 2016.

    Not in our library10.1001/jamaneurol.2016.2642

32. 32.

    Mormino EC, Papp KV, Rentz DM, Schultz AP, LaPoint M, Amariglio R, Hanseeuw B, Marshall GA, Hedden T, Johnson KA, Sperling RA. Heterogeneity in Suspected Non-Alzheimer Disease Pathophysiology Among Clinically Normal Older Individuals. JAMA neurology. 2016.

    Not in our library10.1001/jamaneurol.2016.2237

33. 33.

    Wisse LE, Butala N, Das SR, Davatzikos C, Dickerson BC, Vaishnavi SN, Yushkevich PA, Wolk DA. Suspected non-AD pathology in mild cognitive impairment. Neurobiology of aging. 2015;36(12):3152-62.

    Not in our library10.1016/j.neurobiolaging.2015.08.029

34. 34.

    Nelson PT, Head E, Schmitt FA, Davis PR, Neltner JH, Jicha GA, Abner EL, Smith CD, Van Eldik LJ, Kryscio RJ, Scheff SW. Alzheimer's disease is not “brain aging”: neuropathological, genetic, and epidemiological human studies. Acta neuropathologica. 2011;121(5):571-87.

    Not in our library10.1007/s00401-011-0826-y

35. 35.

    Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jicha GA, Jellinger KA, Kovacs GG, Knopman D, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee AC, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein TD, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL, Wisniewski T, Woltjer RL, Yamada M, Nelson PT. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica. 2014;128(6):755-66.

    Not in our library10.1007/s00401-014-1349-0

36. 36.

    Jack CR, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, Shaw LM, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Pankratz VS, Donohue MC, Trojanowski JQ. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-16.

    Not in our library10.1016/s1474-4422(12)70291-0

37. 37.

    Barnes J, Ridgway GR, Bartlett J, Henley SM, Lehmann M, Hobbs N, Clarkson MJ, MacManus DG, Ourselin S, Fox NC. Head size, age and gender adjustment in MRI studies: a necessary nuisance? Neuroimage. 2010;53(4):1244-55.

    Not in our library10.1016/j.neuroimage.2010.06.025

38. 38.

    Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML, Vasdev N, Dickerson BC, Gomperts SN, Growdon JH, Johnson KA, Frosch MP, Hyman BT, Gomez-Isla T. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Annals of neurology. 2015;78(5):787-800.

    Not in our library10.1002/ana.24517

39. 39.
    An autoradiographic evaluation of AV-1451 Tau PET in dementia · 2016

    No notice
40. 40.

    Jagust W. Vulnerable neural systems and the borderland of brain aging and neurodegeneration. Neuron. 2013;77(2):219-34.

    Not in our library10.1016/j.neuron.2013.01.002

Cited by papers we hold 6

• Quantification of amyloid PET for future clinical use: a state-of-the-art review · 2022
  No notice
• Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline · 2021
  No notice
• Sex-dependent alterations in the physiology of entorhinal cortex neurons in old heterozygous 3xTg-AD mice · 2020
  Not checked
• Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders · 2020
  No notice
• Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer’s disease · 2020
  No notice
• Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research Framework · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.